Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines

Inclusion Criteria: * In good general health * Moderate to severe lateral canthal lines when evaluated at rest based on the investigator's global assessment * Moderate to severe lateral canthal lines when evaluated at rest based on the patient assessment of severity Exclusion Criteria: * Any neurological condition that may place the subject at increased risk with exposure to botulinum toxin type A such as amyotrophic lateral sclerosis and motor neuropathy, Lambert-Eaton syndrome, and myasthenia gravis * Muscle weakness or paralysis, particularly in the area receiving study treatment * Active skin disease or irritation or disrupted barrier at the treatment area * Active eye disease or irritation * Eyelid ptosis, excessive dermatochalasis, deep dermal scarring, or inability to substantially effect the LCL to be treated by manually spreading the skin apart * Use of topical prescription retinoid product(s) in the lateral canthal areas during the 3 months prior to Screening * Undergone any procedures that may affect the lateral canthal region during the 12 months prior to Screening * Treatment with botulinum toxin type A in the lateral canthal areas in the 6 months prior to Screening or 3 months anywhere else in the body